Navigation Links
Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
Date:9/10/2007

The once-daily HIV treatment would greatly increase effectiveness for patients, but Gilead Sciences and Merck and Co. have failed to register it

in countries where it is needed most

LOS ANGELES, Sept. 10 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today called on Gilead Sciences and Merck to immediately register and distribute the three-in-one, once daily lifesaving HIV treatment, Atripla, in developing countries. When Atripla first received approval from the Food and Drug Administration (FDA) in July of 2006, advocates like AHF applauded the production of a single, once-a-day drug as a landmark step in treating HIV. However, since its approval, little progress has been made in expanding the availability of the treatment in the developing world, where only 28% of those in need of treatment were able to access it as of December 2006. Efforts made by AHF to clarify what countries currently can purchase Atripla at the announced $613 per patient per year access price have gone unanswered.

"This treatment is a standard therapy in the United States. It is on the World Health Organization's Essential Medicines List, and is an antiretroviral drug regimen that could greatly benefit patients everywhere while reducing costs in the long term," said Michael Weinstein, AIDS Healthcare Foundation President. "The fact that Gilead and Merck appear to be unable or unwilling to make it available in resource-poor countries is deeply troubling, and causing unnecessary suffering. Gilead and Merck should immediately begin making this treatment available to the rest of the world, or license it out to a generic drug manufacturer, such as Cipla, which already produces a generic version in India, that will. In the instances where the registration process has been initiated such as in the European Union, governments must also recognize their roles and streamline the necessary approval processes to facilitate quick distribution of these lifesaving drugs."

The key value of an all-in-one, one pill per day HIV treatment regimen is the reduced pill burden required for patients. Currently, the most widely used regimen for treatment naive patients consists of a combination of at least two pills taken twice per day, often required to be taken with food and during mid-day hours. Atripla, however, only requires a single pill to be taken once daily without food before bed.

"As we have seen in many of our clinics, pill burden and side effects can be challenging for patients to become accustomed to, and they are among the primary reasons patients do not follow their treatment regimens," said Dr. Homayoon Khanlou, AIDS Healthcare Foundation's Chief of Medicine. "With a complete daily treatment regimen in one pill, the advantage goes much further than simply fewer pills and fewer side effects. The ease of treatment results in improved adherence with more patients taking their medication as prescribed, which greatly increases the effectiveness of treatment. This also results in fewer patients developing resistance to the drugs, and from having to move on to more expensive second-line drugs."

AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 15 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at http://www.aidshealth.org.

If you have received this news release in error and do not wish to receive future advisories, or if they should be directed to someone else in your organization, please call (323) 860-5262. Alternatively, you may fax your updated information or your request for removal from our list to (323) 962- 8513 or e-mail jennifer.ramirez@aidshealth.org.


'/>"/>
SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
5. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
7. The American Liver Foundation Urges Cautious Optimism about CDC Report on Declining Acute Hepatitis Infection Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... YORK , May 27, 2016 ... biotechs, drug manufacturers, health insurance companies all falling under ... small healthcare companies. While not often talked about, these ... The United States is by far ... world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In ... Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... casual readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven ... tech within the industry, from leading advocates, associations and industry leaders such as ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
Breaking Medicine News(10 mins):